Enzo Biochem, Inc. (NYSE:ENZ) Report on Annual Meeting Voting Results

Enzo Biochem, Inc. recently disclosed the outcome of its Annual Meeting held on January 15, 2025. At the close of business on November 27, 2024, which marked the record date for the Annual Meeting, the company had 52,244,074 shares of common stock outstanding and entitled to vote. Of these, holders representing 41,656,697 shares were present in person or by proxy, establishing a quorum for conducting business.

During the meeting, shareholders voted on several key matters. Firstly, Steven J. Pully, Bradley L. Radoff, Kara Cannon, and Jon Couchman were elected to the Board to hold office until the company’s 2025 Annual Meeting, and until each director’s successor is elected and qualified. The shareholders also approved, through a nonbinding advisory vote, the compensation of the company’s named executive officers as detailed in the Proxy Statement.

Furthermore, the appointment of EisnerAmper LLP as the company’s independent registered public accounting firm for the fiscal year ending July 31, 2025, was ratified. Lastly, the shareholders voted to hold a shareholder advisory vote to approve executive compensation annually on a nonbinding advisory basis.

The voting results for each proposal were as follows:

– Proposal 1 – Election of Board of Directors:
– Steven J. Pully: 20,196,495 votes for, 5,511,572 votes against, 4,866,125 votes withheld, and 11,082,505 broker non-votes.
– Bradley L. Radoff: 20,084,143 votes for, 5,625,433 votes against, 4,864,616 votes withheld, and 11,082,505 broker non-votes.
– Kara Cannon: 22,884,624 votes for, 2,825,303 votes against, 4,864,265 votes withheld, and 11,082,505 broker non-votes.
– Jon Couchman: 23,038,697 votes for, 2,677,879 votes against, 4,857,616 votes withheld, and 11,082,505 broker non-votes.

– Proposal 2 – Approval of executive officers’ compensation:
– 19,623,656 votes for, 6,145,891 votes against, 4,804,645 abstentions, and 11,082,505 broker non-votes.

– Proposal 3 – Ratification of EisnerAmper LLP appointment:
– 34,132,481 votes for, 2,510,001 votes against, 5,014,215 abstentions, and 0 broker non-votes.

– Proposal 4 – Frequency of holding shareholder advisory vote on executive compensation:
– 25,260,960 votes for one year, 43,370 votes for two years, 329,490 votes for three years, 4,940,372 abstentions, and 11,082,505 broker non-votes.

Enzo Biochem, Inc.’s Chief Financial Officer, Patricia Eckert, signed the report on behalf of the company on January 16, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Enzo Biochem’s 8K filing here.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.